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Abstract 
Nutrigenomics covers disparate fields of nutrition science and has been defined in many 
different ways. In fact, this emerging field of science has multiple facets, many of which 
do not generate the same ethical issues. In particular, different ethical issues emerge 
concerning the extent to which nutrigenomics may actually improve global health, i.e., in 
terms of worldwide improvement of health, reduction of disparities, and protection 
against global threats that disregard national borders. Nutrigenomics raises many hopes 
and expectations on that score. However it remains unclear and controversial whether 
nutrigenomics studies and their actual or potential applications will actually benefit 
developing countries and their populations. Different forces may drive the choice of 
research priorities and shape the claims that are made when communicating the goals 
or the results of nutrigenomics studies and applications. This article proposes to assess 
expectations and claims in nutrigenomics, with respect to their respective potential 
impact on global health and the ethical issues they raise. Nutrigenomics is and should 
be more than premature claims and much debated promises about personalized 
nutritional interventions on individuals. Beyond questionable commercial claims, 
nutrigenomics is also knowledge about and recognition of the considerable impacts of 
underfeeding and malnutrition on the genome (and epigenome) integrity and stability. As 
such, nutrigenomics research is a valuable opportunity to revive and give strength to the 
debate about the unacceptable consequences of hunger and malnutrition worldwide, 
and to support a newly and potentially significant convergence in research priorities that 
could benefit both developed and developing countries. 
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1. Introduction 
 Nutrigenomics is a new application context for genomics technologies that 
focuses on the bidirectional study of genetic factors influencing host (individuals’ or 
populations’) responses to diet as well as effects of bioactive constituents in food on 
host genome and gene expression [1, 2]. This bidirectional approach to the study of 
genome-diet interaction creates a dual avenue for tangible nutrigenomics applications. 
Nutrigenomics is often described as one of the latest applications of genomics 
technologies in the field of personalized health interventions or personalized medicine, 
following the science of pharmacogenetics and pharmacogenomics. Yet, as it will be 
shown in this article, nutrigenomics goes beyond personalized health interventions. It 
covers disparate fields of nutrition science, which may pursue different goals and thus 
have multiple facets. Consequently, different ethical issues emerge, particularly in 
regard to the extent to which nutrigenomics may improve global health.  
 
There is no common understanding of the term “global health” [3]. Global health “is a 
field that encompasses […], processes, and institutions needed to create the conditions 
for people throughout the world to attain the highest possible level of physical and 
mental health. The field seeks to facilitate health-promoting behaviour among the key 
actors that significantly influence the public’s health, including international 
organizations, governments, businesses, foundations, the media, and civil society” 
(Modified from Gostin and Taylor, 2008, [4, p. 55]). Gostin and Taylor [4] consider that 
global health mainly results from the globalization of public health beyond national 
borders. Other distinctions have been made between public health and global health, 
but it is worth noting that while global health raises specific ethical, social, legal and 
economic challenges, it also targets whole populations and as such, it also generates 
issues that commonly arise within national public health agendas. Therefore, 
considerations relating to public health remain crucial when addressing global health. In 
this article, focus will be put on worldwide improvement of health, reduction of 
disparities, and protection against global threats that disregard national borders, both in 
terms of public health and global health. 
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Many promises have been made regarding the potential outcomes of nutrigenomics 
research. Some of them will likely be fulfilled while others must be considered as 
premature until we have a full understanding of the interactions between genomics, 
nutrition and health. There are, of course, compelling reasons to think globally in terms 
of health when we address these promises and face the challenges that derive from 
them.  
 
Firstly, despite their demonstrated increasing rates worldwide, chronic diseases remain 
surprisingly neglected in the global health agenda [5]. Because of changes in dietary 
and lifestyle habits – a phenomenon that can be linked to the whole globalization 
process – developing countries now face a fast “epidemiological accumulation” [6, p. 14] 
of non-communicable and infectious diseases and must cope with urgent and competing 
health priorities. Non-communicable diseases (NCDs) – especially cardiovascular 
diseases, cancers, chronic respiratory diseases and diabetes – caused 60% of all 
deaths globally in 2005 (estimated at 35 million deaths). Total deaths from NCDs are 
projected to increase by a further 17% over the next 10 years [7, 8]. By 2020, it is 
predicted that NCDs will account for 80 percent of the global burden of disease, causing 
seven out of every 10 deaths in developing countries [9]. This places a considerable 
(double) burden on limited health budgets, in particular in emerging economies. Thus, 
chronic diseases cannot be seen anymore as a national health concern in rich countries 
only and the promises of nutrigenomics must be addressed with respect to this current 
growing epidemic, both in developed and developing countries. 
 
Secondly, according to the Food and Agriculture Organization of the United Nations 
(FAO), food prices remain high in developing countries [10-12]. While commodity prices 
have fallen back from their peaks since 2008, they remain substantially higher than a 
year ago and in most cases more than double their level in mid-2006 [13]. Moreover, the 
number of undernourished people has actually increased by 75 million to more than 920 
millions in 2007 [14]. Concerns resulting from this situation are exacerbated by striking 
socioeconomic disparities and inequities in access to healthcare, let alone genomics 
technologies, as much as to basic nutrition between rich and poor countries and within 
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developing countries themselves. Nutrigenomics research and its potential global 
applications cannot be considered without respect to this ongoing food crisis, global 
recession, and urgently needed measures aiming to fight hunger, malnutrition, poverty 
and inequities both in access to food and healthcare.  
 
The assessment of the potential impact and applications of nutrigenomics for global 
health “demands a vision that reaches beyond the research horizon” [15]. As stated by 
many authors, it is challenging to determine to what extent genomics, including 
nutrigenomics, may result in evidence-based public health strategies [16-18]. Many 
chronic diseases are multifactorial and social and environmental determinants of health 
are worth emphasizing as genetic/genomic factors. At this stage, large-scale genomic 
and epidemiological studies are still needed for translating scientific discoveries into 
global health interventions. Yet, rapid advances in genomics and accompanying 
technologies are triggering a shift in the comprehension of health and disease as well as 
in the understanding of new approaches to prevention and therapy [16].  
 
Moreover, nutrigenomics for global health demands a conceptual shift in both genomics, 
nutrition science, and public health: genomics needs to understand how it can include 
nutrition science as well as public health aspects in its agenda while nutrition science 
and public health need to analyze how genomics changes the concept of public health 
concerning nutrition. It also demands a conceptual shift in bioethics: it will require a 
proportional balance between providing strong protection of individuals’ and populations’ 
interests and enabling them to benefit from nutrigenomics advancements, not only in 
regard to their availability but also to their accessibility both in developed and developing 
countries.  
 
The integration of nutrigenomics into global health programs will be one of the most 
important future challenges for health-care systems and will require organized efforts of 
society. A major ethical question is how these scientific endeavors will be handled in 
order to develop and promote sound and well thought-out global health programs.  
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Advances in our understanding of the human genome have raised high hopes both for 
the prediction and prevention of diseases long before they occur [19], and for the 
development of more effective treatments [20, 21]. Similarly, expectations raised by 
nutrigenomics are high. Potential or current applications of this new field of science have 
been described and communicated in different ways by various stakeholders. Yet, in 
order to avoid serious adverse consequences, including the loss of public confidence in 
genomics (and its current clinical evidence-based applications), it is urgent to distinguish 
goals and expectations from premature or unreasonable claims, as well as to identify 
those future applications that are likely to be the most promising in terms of global 
health. 
 
2. Nutrigenomics: goals and expectations 
 Since the advent of nutrigenomics, many (if not most) claims relating to its 
promises have emphasized the use of personalized nutrition interventions in order to 
prevent the onset of severe chronic diseases in individuals or populations with specific 
genetic predispositions. In this respect, nutrigenomics, as it is stated, “can be used [not 
only] to prevent, [but also to] mitigate or cure chronic disease”, through personalized 
“dietary intervention based on knowledge of nutritional requirement, nutritional status 
and genotype” [22]. As such, nutrigenomics targets apparently healthy individuals with 
genetic predispositions for specific diseases or health conditions, but also patients in 
whom a chronic disease has already appeared. Thus, for instance, some authors argue 
that nutrigenomics could eventually allow us to give specific nutritional advice to 
population groups in which the frequency of a deleterious mutation is high [23, p. 459]. 
Authors even anticipate the use of gene therapy in the field of nutrigenomics, arguing 
that “recombinant genes might also be implanted in people to better adapt them to a 
given diet” or to prevent certain deficiencies resulting from genes-nutrition interactions 
[24]. 
 
The most targeted diseases or health conditions in nutrigenomics research are notably 
various forms of cancer, diabetes, obesity, gut disorders, and cardiovascular diseases. 
Nevertheless, it must be stressed that other nutrigenomics studies – mostly preclinical – 
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focus on the interactions between specific nutrients, gene expression (including age-
related gene-expression alteration) and synaptic plasticity, cognitive development, and 
brain disorders such as Alzheimer’s disease or, more recently, Down syndrome [25-27].  
 
Yet, some private firms that are already (and likely prematurely) selling nutrigenetics 
tests to the public (see Box 1) have significantly broadened the scope of allegedly 
personalized nutrigenomics applications by suggesting that nutrigenetics tests can be 
used to “control health and well-being” in general [37], but also to help people with 
genetic predispositions to “joint issues”, “thinning bones”, “inherited depression 
tendency”, and “propensity to crave sugar” [38]. Some even emphasize the promises of 
nutrigenomics in terms of physical, cognitive and even aesthetic enhancement. Thus, 
allegedly, in the future, a juice designed according to a consumer’s “genetic chemistry” 
could help the latter “to appear younger and more vigorous”, “to be mentally sharper” 
and “to be more appealing to romantic partners” [39]. 
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Box 1 
 
 
Direct-to-consumer “nutrigenetics” tests 
 
Much has been said and written about the growing market of direct-to-
consumer (DTC) genetic tests lately [28-32]. As their name indicates, these 
tests are offered to the public directly, namely with no involvement of a 
licensed physician. Consumers are approached through advertisements on 
the Internet or other media and attracted by claims whose validity or 
foundation generates many concerns. The field of nutrigenomics has not been 
immune to this commercial marketing, several private firms being offering 
“nutrigenetics tests” and dietary recommendations or designed vitamins 
formulas that would be, allegedly, tailored to their consumers’ genetic profile 
and predispositions to specific multifactorial diseases. Major concerns have 
been expressed in this regard, in particular with respect to: ‐ The validity and clinical utility of these tests, and the lack of standard of 
evidence that would allow an appropriate assessment of the efficacy 
and beneficence of “nutrigenetics tests”; ‐ The lack of medical and genetic counseling to the consumer pre- and 
post-testing and, by the same token, concerns about the validity of the 
consent given by the consumers and the risks involved by the potential 
misinterpretation of the test results; ‐ The validity of dietary recommendations allegedly based on consumers’ 
genetic profile; ‐ The promotion of purchasing dietary supplements that are often 
overpriced, and even potentially harmful for the consumer’s health; ‐ The risks of deceit and fraud, if not outright scams, that result from 
biased commercial advertisement; ‐ The general lack of oversight and quality control issues.  ‐ The protection of the privacy and confidentiality of consumers [33]. 
 
Despite restrictive recommendations and policies [34-36] and the enforcement 
of more strict regulations in certain countries and certain states in the U.S. 
[28], this market does not seem to run out of steam. As argued in this paper, 
beyond justified and serious concerns about the current validity of 
“nutrigenetics tests”, it must be stressed that this market is inscribed in a 
nutrigenomics approach that mainly targets well-off consumers and focuses 
on individual (and mostly premature!) applications. As such, it does not only 
generate serious ethical issues about equity and justice in access to 
nutrigenomics applications, but it will also likely not benefit global health or 
developing countries.   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Knowledge resulting from nutrigenomics research has also raised new expectations 
regarding the development and/or the engineering of food that would contain the optimal 
concentration of certain micronutrients (for individuals or given populations), for 
instance, in order to meet human needs, prevent certain diseases and promote optimal 
health in sustainable ways [24, 40-42]. As argued by some authors, certain genomics 
technologies in combination with other –omics sciences, have the potential to generate 
a more complete picture of the composition of food and feed products, to optimize crop 
trait development, and to enhance diet and health [43]. Here, nutrigenomics lays at the 
crossroads of plant nutrition research, human and plant molecular biology, and even 
food processing and production, agriculture sciences and genetic engineering [44]. In 
this field, while it may be claimed that nutrigenomics knowledge could be of interest in 
the engineering of genetically modified organisms, expectations have mainly been linked 
to functional foods and nutraceuticals. Agriculture and Agri-Food Canada define 
functional foods as conventional foods that have physiological benefits and/or reduce 
the risk of chronic diseases beyond basic nutrition. Nutraceuticals are defined as 
products isolated or purified from foods, generally sold in medicinal forms not usually 
associated with foods, and that have a physiological benefit or provide protection 
against chronic diseases [45]. Yet, there is no consensus on such definitions and it is 
plausible that nutrigenomics knowledge might be used to develop and design a new 
generation of functional foods and nutraceuticals. It must be noted that some private 
firms already offer vitamins or vitamin formulas allegedly designed according to their 
consumers’ unique genetic profile (“vitamins that are uniquely yours based on your one-
of-a-kind genetic code” [46]) (See Box 1). In another perspective, it has been suggested 
that (nutri)genomics knowledge could bring useful information to control meat production 
and improve meat quality in nutritionally restricted environments. Studies have been 
conducted to understand the interactions between genes, nutritional restriction and 
muscle development in livestock and the capacity to exhibit compensatory growth after 
restriction is relieved [47].  
 
Finally, it is crucial to stress that nutrigenomics does not (and should not) only target 
individuals with genetic predispositions for specific diseases or health conditions that 
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could be triggered or influenced by dietary factors. Indeed, beyond personalized 
applications, nutrigenomics can also be described as a tool used to study and explain 
the mechanisms by which diet, food, nutrients and other dietary chemicals impact the 
integrity or structure of the human genome and/or alter gene expression in each of us 
and, by the same token, in whole populations, regardless of pre-existing genetic 
susceptibilities for specific diseases. The best illustration of this important goal is the 
growing research in epigenomics and nutrition, aiming to study and explain how nutrition 
(including malnutrition and undernutrition) in utero and in early postnatal life may 
influence health and the onset of chronic diseases later in life [48-53]. Such an example 
also demonstrates that the goal of nutrigenomics is not just about avoiding the onset of 
specific diseases in individuals with pre-existing genetic predispositions that could be 
triggered by food. Nutrigenomics should also aim to promote optimal health on a global 
scale and prevent damages on the genome’s stability and integrity that could create or 
increase genetic predispositions or risks to develop chronic diseases. 
 
All expectations and claims relating to current or future potential nutrigenomics 
applications must be assessed according to their respective merit and, in particular with 
respect to the scientific bases on which they are grounded. In this respect, while much 
research is still needed in this field, it is crucial to keep in mind that there are already 
well-documented examples of clinically significant nutrigenetics interactions. Severe 
adverse reactions to certain foods resulting from specific individual genetic variations 
have been reported and scientifically demonstrated in such cases as inherited deficiency 
of glucose-6-phosphate dehydrogenase (favism) [54, p. 47] or phenylketonuria [55]. 
These examples illustrate how genetic differences may explain why certain individuals 
suffer from severe reactions to specific foodstuff, while others do not. Moreover, the 
number of genes identified by their nutrigenomics potential has significantly increased in 
the recent years [56]. Potential and useful nutrigenomics applications in public health are 
also supported by the results of recent studies that show, among other examples, that it 
may be possible to identify subgroups that would actually benefit from folic acid 
supplements [57], or that a minimum amount of olive oil might be needed to turn on 
genes that contribute to protect individuals against atherosclerosis [58]. 
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Given the aforementioned expectations including questionable commercial claims, but 
also already well-documented evidence of clinically relevant gene-nutrition interactions, 
which nutrigenomics research and applications may actually promote global health and 
benefit developing countries? To attempt to answer such a question, it is first necessary 
to address the complexity of nutrigenomics itself and the current limitations of its 
potential applications in public health. A lack of appreciation of the complexity of this 
science and its potential applications, but also a lack of consideration of the context in 
which it develops may lend itself to premature claims that could occur at the expense of 
realistic promises for global health and developing countries.  
 
3. Nutrigenomics and public health: complexity and uncertainties 
 The possibility of a more efficient science of the prevention and surveillance of 
diseases also illuminates the field of nutrigenomics for global health, where 
nutrigenomics knowledge could provide tools enhancing the capacity of public health 
authorities to promote health and prevent diseases. However, a major challenge for 
public health authorities will be the effective integration of nutrigenomics information into 
public health responses, especially for the identification/treatment of chronic diseases 
that constitute a serious burden to populations and are costly for health care systems. 
Also, in addition to the well-known complexity of genomics association studies [59, 60] 
and uncertainties about the efficacy of potential nutrigenomics applications in public 
health [61], nutrigenomics research and applications face significant challenges as one 
considers the complexity and variability of nutrition and foods and their multiple targets 
[62, 63]. 
 
Although nutrigenomics could initiate a transformation of the “one size fits all” paradigm 
in global health, there are concerns about “blind faith” in or overly optimistic views of 
scientific progress resulting from the most recent research in this field [64]. Some 
commentators state that it is still premature to associate nutrigenetics variants with the 
expression of complex diseases [18]. They argue that, given the interaction of the 
genetic and environmental factors behind complex diseases, the attempts to link 
relevant genes with the expression of such diseases are invariably simplistic and offer 
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little real hope for practical diagnostics and treatments. Moreover, it would be very 
challenging to anticipate individuals’ reactions to receiving genetic information that is 
probabilistic and derived from multiple sources. Nutrigenomics illustrates the complexity 
of biological processes, the importance of gene-gene and gene-environment 
interactions. Its power must also lay in the application of other mainstream public health 
interventions – promoting healthy behaviors or acting on environmental factors – 
directed at sub-groups of populations segmented according to their risks. As a result, it 
is important not to forget that in order to prevent a fatalistic attitude from at-risk people, 
nutrigenomics applications in public health must also consider other health 
determinants. 
 
Nutrigenomics forms a complex field of knowledge, susceptible to being misunderstood 
by non-experts. This is a major challenge in public health. The notion of an evaluation of 
risks and susceptibilities better conveys the complexity of current knowledge about 
multifactorial diseases than the prediction thereof. Nonetheless, the idea of risk remains 
abstract and is difficult to grasp for non-experts. The diversity of their perceptions 
reveals itself in the literature [65-67]. Emphasizing these nuances buttresses the 
recommendation to spread genomic knowledge so as to inform and educate those non-
experts that will be called upon to participate in the process of integrating nutrigenomics 
into global health [66], but also to raise the awareness of experts on the impact that 
language can have, whether it be when reporting results, or in direct contact with people, 
either in a clinical work or in a preventive context. 
 
Such challenges illustrate the current limitations and uncertainties linked to the potential 
efficacy, risks and benefits of nutrigenomics applications in public health systems within 
national borders themselves, but such limitations are obviously also relevant when it 
comes to addressing the promises of nutrigenomics for global health. The long-term 
development of global health genomics will require an appropriate integration of the 
scientific, clinical, economic, social and ethical dimensions as well as the strengthening 
of global health ethics. In this perspective, in a recent article, Gwinn and Khoury [68] 
identified three levels for the integration of genomics into public health. Although the 
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work of Gwinn and Khoury [68] is directed at public health in the United States of 
America, it might also be relevant for global health. The first is related to the possibility of 
conducting population health research in genomics. The impact of new findings in 
genomics could be limited without large cohort studies confirming these findings and 
illustrating the risk factors related to specific diseases. The collaboration of different 
fields of research is essential and would increase the impact of research in global health. 
The second level concerns the development of scientific evidence regarding the value of 
genomic information. This emphasizes the importance of disseminating information 
emerging from genomics research to ensure that public health professionals receive a 
clear demonstration of the clinical validity and utility of genomics. It implies that health 
professionals should have access to training on new genomic tools that could bring 
significant changes in global health. A number of technologies have proven their clinical 
value, but to be used properly, public health institutions need personnel trained in using 
complex information [69]. For this purpose, international networks are being developed 
to spread information about genomics and global health (e.g.: GRAPH Int. [70]). The 
third level refers to the integration of genomics into global health practice. According to 
the authors, the realization of this process requires “careful policy planning and 
development that recognizes the complexity of genomics while building on approaches 
that have been successful in evaluating other health technologies” [68]. Recently, a 
strengthening of public health ethics has been launched at the US Centers for Disease 
Control and Prevention to address specific public health program concerns, including 
genomics [71]. The authors anticipate that as public health ethics activities grow, 
benefits will be seen in greater participation and partnership with affected stakeholders 
and strengthened public trust in health recommendations. 
 
4. The major ethical challenges of nutrigenomics for global health: 
Stigmatization, discrimination and social justice 
 In addition to scientific complexity and current uncertainties, nutrigenomics 
applications for global health face major ethical challenges. In order to keep its promise 
of improving health, nutrigenomics needs to see its scientific progress harmonized with 
human dignity and social justice as expressed through adherence to fundamental ethical 
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principles. Some of the ethical issues raised by nutrigenomics will be the same as those 
raised by the development of genomics research and applications in general: notably, 
genetic exceptionalism and reductionism [72-74], protection of privacy and 
confidentiality, and issues relating to autonomy and informed consent in clinical care and 
research. While such challenges have just begun to be addressed in regard to 
nutrigenomics (see for instance, [1, 23]), other ethical issues such as stigmatization, 
discrimination and social justice may well arise specifically or with more strength during 
the development of nutrigenomics applications for global health, in particular in emerging 
economies and vulnerable populations [see also Box 2].  
The implementation of more accurate methods of prevention and surveillance brings out 
the stigmatization and discrimination issues encountered in global health ethics. Is there 
a risk of stigmatizing sub-populations because of their genetic susceptibilities? Will the 
use of genomics technologies lead to new inequalities among people? Which segments 
of the population will be subject to surveillance and on what grounds? Even if the risks of 
stigmatization or discrimination might be exaggerated, the fears might hinder the 
development of nutrigenomics, thereby restricting its potential benefits for populations. 
Such questions underline the importance of not loosing sight of the ethical principles at 
the root of global health ethics [75-77]. Because of the power imparted to public health 
authorities, the ethical integration of nutrigenomics into global health requires the 
informed awareness of lay citizens, and eventually their participation in the formulation 
of public policy in a framework of respect for local and cultural particularities [64]. 
Otherwise, the situation might evolve toward contributing to social inequalities or causing 
undesirable harm. Most genetics experts recognize the importance of public awareness 
[75, 78] for avoiding stigmatization and discrimination.  
 
Thereafter, it becomes necessary to reflect on the nature of the terms used in scientific 
publications and on nutrigenomics websites. Some ways of reporting results, albeit 
proper from a strictly scientific point of view, can carry messages that are detrimental to 
certain groups, with the potential to reinforce prejudice and thus be harmful to 
identifiable social groups, as in the case of racial prejudice [67]. In public health, a 
constant practical concern leads to special care being taken in how preventive 
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messages are conveyed to the public, so as to limit any prejudicial effects on target 
populations, whether it be through stigmatization, marginalization or an incitement to 
judgmental attitudes [79]. 
 
Moreover, research focusing on Caucasian populations may restrict the range of groups 
and/or populations that might likely benefit from nutrigenomics developments. As a 
matter of fact, the genetic diversity of human populations is a challenge to the 
development of personalized dietary interventions [80]. Small, specific (and likely more 
vulnerable) groups could become the “orphans” of nutrigenomics. These are major 
discrimination and justice concerns in nutrigenomics research and potential applications. 
The same is true if nutrigenomics research focuses on western diets or foodstuffs that 
cannot be produced or that are not accessible or culturally relevant to populations in 
developing countries.  
 
In developing countries and emerging economies, the potential stigmatisation and 
discrimination also relies on the non-access to nutrigenomics services. Of particular 
interest is how nutrigenomics advances will affect the health of people living in the 
developing countries. In fact, genomics and related technologies should be used to 
narrow the existing unethical inequities in global health [81]. The reality that much of the 
advances in genomics were made, and in part are owned, by the developed world has 
given rise to the concern that a genomics divide will be created that will further widen the 
equity gap in health between rich and poor nations. In this respect, current patents and 
market exclusivity systems raise serious ethical issues, notably in terms of global justice. 
Similar concerns have been expressed in the field of pharmacogenetics [82], for 
instance, and will not be developed in this article. However, concrete measures and 
precautions should be taken to address such concerns, failing which there is little doubt 
that patents on nutrigenomics discoveries could accentuate existing injustices 
concerning food access and inequities in global health as much as in access to future 
potential nutrigenomics applications. Nutrigenomics for global health calls for the right of 
whole populations to benefit from its results, not only individuals who have the sufficient 
resources to access them. The concept of “common good” might also be part of the 
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solution to this ethical dilemma [83]. It stipulates that in an era of liberalism and 
globalization, the creation of public goods compensates for the inequalities resulting 
from an inequitable distribution of genomic technologies. “Global public goods are 
defined as goods that are (…) enjoyable by all without detriment to others” [84]. To some 
experts, genomic knowledge corresponds to the definition of a public good because it 
belongs to the common heritage of humanity [84, 85], of its “common ownership” and 
therefore should be a universally accessible resource. In this perspective, by promoting 
a “common ownership” of genomic knowledge, by improving global health and by 
tailoring interventions for populations, nutrigenomics developments could be perceived 
as common goods that respond to the most fundamental needs of individuals (e.g., 
equity, beneficence) while achieving the goals of the community [84].  
 
Research priorities and access to services are central to global health. Another problem 
which has to be addressed in this context is the fact that commercial interests are 
increasingly driving the public research agenda in many developed countries. If 
unchecked, this trend will discourage scientists in academia from pursuing research 
directed at improving the health of people living in the developing countries [86, p. 102]. 
Yet, the current situation has been called the “10/90 divide” [87]. This means that more 
than 90 per cent of medical research resources are targeted at diseases that account for 
only 10 per cent of the global burden of disease (i.e., diseases most relevant to the 
wealthy). Less than 10 per cent of research resources are aimed at those that account 
for 90 per cent of the global burden of disease (i.e., diseases that mostly affect the 
poor). In addition to the increased funding needed to make existing (and sometimes 
inexpensive) medicines more accessible to impoverished populations, a boost in 
resources is needed to fuel R&D in areas most relevant to the poor.  
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BOX 2 
Are there any ethical challenges unique to nutrigenomics? 
 
As mentioned in section 4 of this article, many ethical issues raised by nutrigenomics will 
be the same as those raised by genomics research and its applications. However, other 
ethical challenges may arise specifically or with more strength during the development of 
nutrigenomics applications. 
 
First, in addition to the complexity of genomics association studies, nutrigenomics 
research must tackle the complexity of diets, food components and the multiple targets 
and effects that different nutrients in different amounts may have in the human body. 
Thus, the assessment of the scientific validity of research protocols, of the scope of 
research results and of the efficacy of potential nutrigenomics applications in public or 
global health is challenging. A lack of any concrete scientific standard of evidence, the 
uncertainty about the potential efficacy of public health measures based on 
nutrigenomics applications, a lack of appreciation of the complexity of nutrigenomics, its 
potential impacts, and the context in which it occurs may create a fertile ground for 
biohype, namely for unrealistic promises, excessive publicity, and premature claims 
made in advertising material. It also raises major issues in the way research results are 
communicated to the public or used by firms to sell nutrigenetics tests to consumers 
(See Box 1). 
 
Secondly, as stated by Bergmann and colleagues (referring to Holm), “[f]ood means 
much more than nutrition. Food is enjoyment as cultural and personal identity. A meal is 
a social event, an important manifestation of relationship with others. This means that 
food is an important aspect of human happiness and well-being, and not only an 
instrument of health” [23, p. 456]. In this respect, the development of nutrigenomics 
along with “personalized medicine” raises major ethical issues. Nutrigenomics can alter 
our relation to food, by medicalizing food choices and eating behaviours. Moreover, 
when targeting healthy individuals, nutrigenomics can blur boundaries between health 
and diseases, and between food and drugs (“nutritional pharmacology”). It broadens the 
scope of health interventions from patients to individuals by supporting the concepts of 
“pre-disease” states and “preemptive nutrition” [88]. 
 
Finally, in terms of global health, the complexity of potential prevention measures based 
on nutrigenomics knowledge (see section 3), but also ethical issues relating to social 
justice and to the risks of stigmatization and discrimination are major challenges on 
which this paper focuses (sections 4 and 5). While such issues are not unique to 
nutrigenomics, they appear with a particular strength when it comes to assess the 
promises of this new field of science. 
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5. What promises for underserved countries? 
 Advocates of global health genomics believe that genomics research will foster 
the development of new genomic tools applicable in a wide variety of public health 
settings [42, 89, 90]. Genetic services related to maternal and child health have been 
offered in many countries since the early 1960s [18, 91] and ongoing efforts and the 
increasing resources devoted to genomics could eventually pave the way for major 
advances in global health. Yet, knowing that the recognition of the significance of 
monogenic diseases and birth defects for public health within developing countries is still 
recent [6, p. 14], it is a safe bet that nutrigenomics research and in particular 
personalized applications aiming to prevent the onset of multifactorial diseases (such as 
the diseases targeted by nutrigenomics) may not be perceived as a priority in and for 
such countries. The current market-driven agenda such as followed by commercial firms 
targeting well-off individuals who can allow paying for allegedly useful nutrigenetics tests 
reinforces such perceptions (see Box 1). Such a market does obviously not support 
global health, equity and social justice, especially when it comes to genetic testing 
services offered in developing countries by private firms that, despite their localization 
within the country itself, explicitly target “medical tourists”, and not local populations [90]. 
 
However, despite such commercial approaches, misconceptions according to which 
nutrigenomics would not be relevant in developing countries must be dispelled. As 
previously mentioned in the introduction, in addition to infectious diseases, developing 
countries are now facing a growing epidemic of the same chronic diseases that are 
found in industrialized countries. Moreover, while underfeeding is still an important issue 
in many of them, emerging economies are also grappling with malnutrition, that has 
accompanied their nutrition transition and the global food and economic crisis. 
Nutrigenomics and epigenomics studies tend to demonstrate that early nutrition is not 
only crucial for children’s physical and cognitive development [48-53], but also for their 
future productivity as adults [92, p. 25; 93]. Such findings demonstrate that the health 
and economic consequences of underfeeding and malnutrition may be for life and even 
intergenerational (or transgenerational) [92, p. 22; 93]. Thus, beyond personalized 
applications aiming to improve individual health or to prevent the onset of chronic 
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diseases in individuals, knowledge from nutrigenomics research could be a powerful tool 
to understand the long-term consequences of underfeeding and malnutrition and could 
be used to improve prevention and nutrition programs targeting whole populations, 
including in developing countries. In this respect, nutrigenomics, along with 
epigenomics, may fall within the global agenda that aims to improve population health, 
but also food security, availability, stability, and access. Moreover, by targeting diseases 
that have become a huge burden in both developed and developing nations, 
nutrigenomics research may also pave the road for a shared agenda in research 
priorities, decreasing by the same token the aforementioned “10/90 divide”.  
 
Yet, much concern has always been expressed around the diversion of scarce 
resources from other but more evidence-based traditional public health measures and 
priorities in developing (but also developed) countries. Such an argument is even 
stronger when it comes to nutrition security and access. However, it is crucial not to 
overlook the potential utility of nutrigenomics within and for emerging economies. 
Nutrigenomics will not address the immediate food needs of poor people or entire 
populations in emerging countries, nor will it put in place high-priority policy measures 
necessary to improve access to basic nutrition and help populations cope with food 
prices or the global economic crisis. The recognition of the impact of environmental 
factors such as socio-economic conditions and disparities on global health, and in 
particular on the health of populations in these countries remains of the utmost 
importance. As for any genomics advances, advances in nutrigenomics for global health 
will have to be assessed with respect to their relative value in the practice and delivery 
of health care compared with the costs and efficiency of current approaches to public 
health, disease control, and the provision of basic preventive medicine, medical care 
and nutrition (Modified from WHO, [86, p. 72]). In any case, food justice and food 
security must be valued at all levels, in all policies. These are goals in themselves and 
any tool that could be used to achieve such goals deserves attention [94]. 
Nutrigenomics could be one of these tools. 
 
  20 
Nutrigenomics raises many hopes and expectations, but it already appears that all 
potential nutrigenomics applications do not all present the same potential benefits nor 
represent the same risks in terms of global health, in particular in underserved countries. 
Given the cultural nature of nutritional habits, the potential variations in genotypes of 
different ethnic populations, nutrigenomics would not likely serve these countries if their 
cultural, ethnic or socioeconomic context is not taken into consideration from the design 
of research protocols to the implementation and evaluation of nutrigenomics 
applications. Nutrigenomics might hold some of its promises in emerging countries if, 
and only if, it is tailored to their respective needs, cultures, health systems and priorities. 
Beyond the costs of such services and social justice issues, one of the major challenges 
will also be to identify the type of nutrigenetics knowledge and services underserved 
countries may actually need in terms of efficacy and cost-efficiency. And to achieve such 
a goal, it is necessary to reflect on how to act wisely considering the many ethical and 
social-policy implications at stake. 
 
6. Conclusions and Future Outlook 
 The ethical debate surrounding nutrigenomics research, debate framed by values 
based on research advances and individuals’ protection, is increasingly being influenced 
by the collective values which characterize nutrition science and public health. Although 
collective values are at the heart of public health activities, the interdisciplinary field of 
nutrigenomics is raising considerable questions for global health [16, 95]. Solid scientific 
evidence of nutrigenomics effectiveness and indicators of health determinants for global 
health need to be evaluated and justified. It has already been argued that a strong 
medicine and public health partnership in the genomics era is needed for the translation 
of most scientific discoveries into benefits for population health, including a commitment 
to evidence-based knowledge integration with several potential genomic applications in 
practice [95]. These efforts should be complemented with an emphasis on health 
services research to evaluate outcomes, over both the short and the long term, including 
attendant costs and benefits in the real world. 
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Nutrigenomics may be perceived in two ways: as a market targeting and benefiting well-
off individuals and / or as a tool to understand gene-diet interactions that may be used to 
promote global health and raise awareness that healthy food matters for everyone 
(everyone who can afford it – many being happy to get any food they can). While certain 
expectations may be realistic, it is legitimate and necessary to question unreasonable 
claims and premature translation into commercial applications that may harm the whole 
field and raise critical ethical issues in terms of global health. 
 
While some of the ethical issues surrounding nutrigenomics are common to any type of 
genomics research, others are more specific to global health and underserved countries. 
Many studies in nutrigenomics seem to focus on an individual approach, when 
personalized nutrition will unlikely solve global health problems and inequalities. In itself, 
a merely commercial approach, targeting individuals, is far from promoting global health, 
social justice and equity in access. However, commercial incentives and practices 
should not be a sufficient reason to claim that nutrigenomics cannot be of benefit for 
global health, including in developing countries and emerging economies where 
societies have to cope with the accumulation of serious burdens: underfeeding as well 
as malnutrition, and an increase of chronic diseases along with a prevalence of 
infectious diseases that remains extremely high. Nutrigenomics will not and never 
replace needed and urgent measures aiming to improve global access to basic nutrition. 
Further, inequities in food access could even be aggravated by potential nutrigenomics 
applications that would require the ingestion of foods that would not be available in the 
poorest countries. Yet, despite major ethical and scientific challenges, the potential 
benefits of nutrigenomics to fight hunger, malnutrition, and chronic diseases must not be 
overlooked. Certainly, the first tangible benefits resulting from this new field of science 
for the developing world is a more clear and striking scientific recognition of the 
devastating effects of underfeeding and malnutrition on genome integrity itself and on 
the health of whole populations and their descendants. We may hope that as such, 
nutrigenomics knowledge will give support to a common global health and research 
agenda that could also benefit the developing world and populations, instead of rich 
countries and well-off individuals only. 
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